FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 171.41

Change

+1.40 (+0.82)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.28 (-0.19%)

USD 40.26B
FHLC Fidelity® MSCI Health Care In..

-0.13 (-0.18%)

USD 2.86B
FXH First Trust Health Care AlphaD..

+0.33 (+0.31%)

USD 1.18B
XHE SPDR® S&P Health Care Equipme..

+0.24 (+0.27%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.08 (+0.32%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

-0.53 (-1.37%)

USD 0.12B
XHS SPDR® S&P Health Care Service..

-1.28 (-1.35%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.12 (+0.43%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.56 (-0.87%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.55 (-1.87%)

USD 0.01B

ETFs Containing FBT

FBT:CA First Trust NYSE Arca Bio.. 99.97 % 0.00 %

+0.14 (+0.47%)

CAD 1.83M
FHM:CA 99.89 % 0.78 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.45% 67% D+ 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.45% 67% D+ 61% D-
Trailing 12 Months  
Capital Gain 27.27% 76% C+ 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.27% 76% C+ 68% D+
Trailing 5 Years  
Capital Gain 28.96% 67% D+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 28.96% 67% D+ 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 1.14% 33% F 39% F
Dividend Return 1.47% 33% F 31% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 11.94% 95% A 74% C
Risk Adjusted Return 12.33% 38% F 31% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.